SCHEMBL3570305

SCHEMBL3570305

Nc1ccc(Cc2ccc3c(c2)C(=CNc2ccc(N4CCOCC4)cc2)C(=O)N3)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.44
CSF1R P07333 1/20 0.41
CHEK1 O14757 3/20 0.40
CHEK2 O96017 1/20 0.40
KIT P10721 1/20 0.40
MARK3 P27448 1/20 0.40
MAPK1 P28482 1/20 0.40
AKT1 P31749 1/20 0.40
MARK2 Q7KZI7 1/20 0.40
AURKB Q96GD4 1/20 0.40
ERBB2 P04626 1/20 0.39
RET P07949 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
AKT2 P31751 1/20 0.39
PAK1 Q13153 6/20 0.39
RORC P51449 1/20 0.38
TGM2 P21980 1/20 0.37
MET P08581 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3574278 0.92 PDGFRB (0.44) PDGFRBCSF1RCHEK1CHEK2KIT
SCHEMBL3584439 0.90 CSF1R (0.42) PDGFRBCSF1RAURKBERBB2RET
SCHEMBL3570303 0.89 AKT2 (0.43) PDGFRBCSF1RCHEK1CHEK2KIT
SCHEMBL5430284 0.87 CSF1R (0.46) PDGFRBCSF1RCHEK1CHEK2KIT
SCHEMBL4705955 0.87 CSF1R (0.46) PDGFRBCSF1RCHEK1CHEK2KIT
SCHEMBL3574274 0.85 PARP1 (0.46) PDGFRBCSF1RCHEK1CHEK2KIT
SCHEMBL3580563 0.84 PDGFRB (0.43) PDGFRBCSF1RAURKBERBB2RET
SCHEMBL4703846 0.83 LCK (0.45) PDGFRBCSF1RRETAKT2PAK1
SCHEMBL5449435 0.83 LCK (0.45) PDGFRBCSF1RRETAKT2PAK1
SCHEMBL4996134 0.82 LRRK2 (0.52) PDGFRBCSF1RKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 PDGFRB 407/4885CSF1R 877/4885CHEK1 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.